TuHURA Biosciences (Nasdaq: HURA) details June 30, 2025 results

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. filed a current report to furnish a press release that outlines its financial results for the three months ended June 30, 2025 and provides a corporate update. The press release, dated August 14, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report on a furnished, not filed, basis under securities laws. TuHURA’s common stock, with a par value of $0.001 per share, trades on the Nasdaq Capital Market under the symbol HURA.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001498382falseAugust 14, 2025TuHURA Biosciences, Inc./NV00014983822025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Nevada		001-37823		99-0360497
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10500 University Center Dr., Suite 110
Tampa, Florida 33612
(Address of Principal Executive Offices, including zip code)
Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		HURA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein

The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No. Document

99.1 Press Release, dated August 14, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TUHURA BIOSCIENCES, INC.
Date:	August 14, 2025	By:	/s/ Dan Dearborn
			Name: Dan Dearborn Title: Chief Financial Officer

FAQ

What did TuHURA Biosciences (HURA) disclose in this 8-K?

TuHURA Biosciences furnished a press release reporting its financial results for the three months ended June 30, 2025 and providing a corporate update, attached as Exhibit 99.1.

Which period do the TuHURA Biosciences (HURA) results cover?

The financial results disclosed by TuHURA Biosciences cover the three months ended June 30, 2025.

Where can investors find the detailed TuHURA Biosciences results and update?

The detailed information is in the press release attached as Exhibit 99.1 to the report, which includes financial results and a corporate update.

Is the TuHURA Biosciences press release considered filed or furnished?

The report states that the information in it, including Exhibit 99.1, is being furnished and is not deemed filed under the Securities Act or Exchange Act, except where specifically incorporated by reference.

On which exchange is TuHURA Biosciences common stock listed and what is the ticker?

TuHURA Biosciences’ common stock is listed on The Nasdaq Capital Market under the trading symbol HURA.

Who signed the TuHURA Biosciences 8-K related to the June 30, 2025 results?

The report was signed on behalf of TuHURA Biosciences by Dan Dearborn, the company’s Chief Financial Officer.